立即登录 | 免费注册
全部学科 | 内科学 | 心血管病学 | 内分泌学与糖尿病 | 神经病学 | 消化病学 | 呼吸病学 | 肿瘤学 | 妇产科学 | 骨科学
疾病中心： 高血压 | 冠心病 | 心力衰竭 | 心律失常 | 脂肪性肝病 | 糖尿病 | 卒中 | 慢性阻塞性肺病 | 子宫内膜异位症 | 乳腺癌 | 肺癌 | 结直肠癌 | 器官移植
Loading
当前位置：期刊中心 > 全球精选文摘 > 文摘导读

罗苏伐他汀对心房纤颤发生率的影响：GISSI-HF试验的次要结果

Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial
Maggioni AP, on behalf of the GISSI-HF Investigators    |    2010/3/4 14:18:32   | 
Eur Heart J  |   2009   |          View at Publisher
专家评级： ★★  |    循证评级： B   |  【全球专家评论】 |   打印| 推荐给好友
上一篇： 心肌梗死后早期植入除颤器
下一篇： 犬心肌梗死后心力衰竭模型中脊髓刺激可改善心室功能并减少室性心律失常
Aims:

This ancillary analysis of the GISSI-HF database aims at assessing the effect of rosuvastatin on the occurrence of atrial fibrillation (AF) in patients with chronic heart failure (HF) who were not in AF at study entry.

Methods and Results:

GISSI-HF was a double-blind, placebo-controlled trial testing n-3 PUFA and rosuvastatin vs. corresponding placebos in patients with chronic HF. Atrial fibrillation occurrence was defined as the presence of AF in the electrocardiogram (ECG) performed at each visit during the trial or AF as a cause of worsening HF or hospital admission or as an event during hospitalization. Among the 3690 patients (80.7%) without AF on their baseline ECG, 15.0% developed AF during a median follow-up period of 3.7 years, 258 randomized to rosuvastatin (13.9%) vs. 294 allocated to placebo (16.0%). Although the difference was not significant at unadjusted analysis (P=0.097) and multivariable analysis adjusting for clinical variables (P=0.067), it became significant after adjustment for clinical variables and laboratory examinations (P=0.039), and for clinical variables, laboratory examinations, and background therapies (P=0.038).

Conclusion:

This study shows that there is some evidence of a beneficial effect of rosuvastatin in terms of reduction of AF occurrence in patients with HF. Larger populations are needed to provide a definite answer to the question. ClinicalTrials.gov Identifier: NCT00336336 (Fig 2).
Figure 2 Figure 2: Kaplan–Meier curves for time to new onset of atrial fibrillation. (Reprinted from Maggioni AP, on behalf of the GISSI-HF Investigators. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J. 2009;30:2327-2336, with permission from The European Society of Cardiology.)
关键词:

请登录后发表评论，点击此处登录。
相关文章

关注糖尿病，聚焦GLP-1！案例征集大赛
时间：2011-3~~2011-11
由中国医师协会主办、礼来国际贸易（上海）有限公司协办、爱思唯尔国际出版集团承办的“精彩案例我分享——关注糖尿病•聚焦GLP-1”案例征集活动将于2011年3月~ 11月在全国范围隆重展开。

关注青光眼患者， 让世界更明亮！
时间：2011-4~~2011-12
《中华眼科杂志》发起，辉瑞制药资助，旨在交流青光眼治疗理念，分享国内抗青光眼药物固定联合治疗经验的病例交流活动.

聚焦哮喘和COPD联合制剂治疗
时间：2010-12~~2011-12
哮喘和慢性阻塞性肺疾病（COPD）是常见、多发的气道炎症性疾病，这类疾病严重影响患者的生活质量。我们特别组织了该类案例征集活动，奖品丰厚，快来参与！

中国选择 达标看我
时间：2011-9~~2012-9
本次活动对典型病例以分享的形式总结临床经验，通过跨专科、多层次的学术交流，对降压治疗方案、疗效进行解析与点评。

 

慢性心衰诊治：规范中求突破
黄峻
2012-2-1
南京医科大学第一附属医院
房颤治疗：手段渐趋丰富 新型治疗药物不断涌现 非药物治疗备受关注
马长生
2012-2-1
首都医科大学附属北京安贞医院
注重老年人群特征 优化管理

刘梅林
2012-2-1
北京大学第一医院老年内科